Treatment of proliferative diabetic retinopathy with anti-VEGF agents.
about
The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment.Novel atypical PKC inhibitors prevent vascular endothelial growth factor-induced blood-retinal barrier dysfunctionMelatonin-mediated cytoprotection against hyperglycemic injury in Müller cellsIntravitreal bevacizumab for proliferative diabetic retinopathy with new dense vitreous hemorrhage after full panretinal photocoagulation.Regulated in development and DNA damage 1 is necessary for hyperglycemia-induced vascular endothelial growth factor expression in the retina of diabetic rodentsTherapeutic Effects of PPAR α on Neuronal Death and Microvascular Impairment.Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): a multicentre phase IIb randomised active-controlled clinical trial.Biomarkers for Diabetic Retinopathy - Could Endothelin 2 Be Part of the Answer?Intravitreal administration of multipotent mesenchymal stromal cells triggers a cytoprotective microenvironment in the retina of diabetic mice.Coexpression of heparanase activity, cathepsin L, tissue factor, tissue factor pathway inhibitor, and MMP-9 in proliferative diabetic retinopathy.VEGF secreted by hypoxic Müller cells induces MMP-2 expression and activity in endothelial cells to promote retinal neovascularization in proliferative diabetic retinopathy.Enhancement of scutellarin oral delivery efficacy by vitamin B12-modified amphiphilic chitosan derivatives to treat type II diabetes induced-retinopathy.Neovascular glaucoma after vitrectomy in patients with proliferative diabetic retinopathy.Novel targets against retinal angiogenesis in diabetic retinopathy.Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration.Could donor multipotent mesenchymal stromal cells prevent or delay the onset of diabetic retinopathy?Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab.An anti-angiogenic reverse thermal gel as a drug-delivery system for age-related wet macular degeneration.Intraocular surgery in a large diabetes patient population: risk factors and surgical results.Heat shock protein-70 and hypoxia inducible factor-1α in type 2 diabetes mellitus patients complicated with retinopathy.Prevalence and treatment patterns of ranibizumab and photodynamic therapy in a tertiary care setting in Malaysia.Diverse roles of macrophages in intraocular neovascular diseases: a review.Association of 150-kDa oxygen-regulated protein with vascular endothelial growth factor in proliferative diabetic retinopathy.Early retinal pigment epithelium dysfunction is concomitant with hyperglycemia in mouse models of type 1 and type 2 diabetes.Differential expression and localization of human tissue inhibitors of metalloproteinases in proliferative diabetic retinopathy.New Scaffold for Angiogenesis Inhibitors Discovered by Targeted Chemical Transformations of Wondonin Natural Products.Unbalanced Vitreous Levels of Osteoprotegerin, RANKL, RANK, and TRAIL in Proliferative Diabetic Retinopathy.Plasma level of miR-93 is associated with higher risk to develop type 2 diabetic retinopathy.Extracellular matrix metalloproteinase inducer (EMMPRIN) is a potential biomarker of angiogenesis in proliferative diabetic retinopathy.Upregulation of Thrombin/Matrix Metalloproteinase-1/Protease-Activated Receptor-1 Chain in Proliferative Diabetic Retinopathy.Comparisons of microRNA expression profiles in vitreous humor between eyes with macular hole and eyes with proliferative diabetic retinopathy.Matrix metalloproteinase-14 is a biomarker of angiogenic activity in proliferative diabetic retinopathy.
P2860
Q31061150-F0958C73-2364-4CF1-ABA3-37266A9FC705Q34313113-2E0CE273-FC58-4980-A42D-1F36C71E645CQ34506566-02A252F5-0C15-4B7F-9C4E-71D30DAABEA8Q34987495-FC53B343-7EED-4368-88F1-39ED41A49746Q35055667-A9055A90-5DE7-4B24-831F-6909365B1DD5Q35078274-75BBCD8F-C194-4CD2-A834-456B16AC2FCDQ35775051-B7B8577D-9BE5-4D6C-A442-1FB20ED8ADC3Q36092355-66E667A3-7DD4-4853-906A-A4D28923B848Q36691521-F2A3EFB3-AFA7-45AE-9137-F52593C51345Q36853911-6A2EB64E-EBFB-4170-AE24-0CF967A98346Q37251091-FEC18918-B8F7-452B-A2AB-8E2CB529C0CAQ37676783-EC2D5C50-9D7B-49CD-B924-D0D20EAC8351Q37696872-62B55E4F-3433-415F-86A9-747621F629EBQ38013679-BD90226A-B233-432C-B0A4-D4608FB1A620Q38030051-07E28DAB-C8E3-481D-95CD-4A42BB2BFCFCQ38115020-34E280D9-8C6B-4914-9274-1EDDEC308BF4Q41091625-CC907EC4-5A84-4C03-A29A-EFA61FDF1591Q41970943-DB8ADE4E-67BE-4D29-B607-C76BC4DB1F40Q44920544-EC4E21E9-0CD4-4031-AD5F-F10ADA174A99Q46527092-1592DFA4-3AC9-4976-BC82-05B4353A6EAEQ47139871-E6476252-DF56-402A-BDF5-29A0BE70A959Q47202861-483C8795-D618-4C4E-AACC-497782853D02Q47446172-49498B87-0325-472C-9494-9FCF45D643C7Q48169124-2C5EAC4A-078F-471C-873A-2D2C6F4BEC19Q48300010-0780A2F0-AB55-4FF2-AC33-5530D1ED9E14Q50066099-2BE67542-E612-4838-8B5E-C4D04D0EEB8CQ50071959-402B4028-520B-4F8A-BC4D-1B4A1AD6D78EQ51069605-52FC1AEC-399D-410D-98CC-AF4B7F0AC79CQ51319850-386EA33C-A121-46B1-B6C3-6CD7D98D9917Q51720742-D7401DA4-67C3-4336-BD2D-FA73B37CAB5FQ54200577-F891E335-A470-4886-9E84-3B3B26BB21FDQ55097343-9CDD4ECD-BB4C-4DEA-91C6-C6DC8BC7C4F7
P2860
Treatment of proliferative diabetic retinopathy with anti-VEGF agents.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Treatment of proliferative diabetic retinopathy with anti-VEGF agents.
@ast
Treatment of proliferative diabetic retinopathy with anti-VEGF agents.
@en
type
label
Treatment of proliferative diabetic retinopathy with anti-VEGF agents.
@ast
Treatment of proliferative diabetic retinopathy with anti-VEGF agents.
@en
prefLabel
Treatment of proliferative diabetic retinopathy with anti-VEGF agents.
@ast
Treatment of proliferative diabetic retinopathy with anti-VEGF agents.
@en
P2093
P2860
P1433
P1476
Treatment of proliferative diabetic retinopathy with anti-VEGF agents.
@en
P2093
Aysha Salam
Raeba Mathew
Sobha Sivaprasad
P2860
P304
P356
10.1111/J.1755-3768.2010.02079.X
P577
2011-02-05T00:00:00Z